RT Journal Article
T1 Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy
A1 Escobar-Lopez, Luis
A1 Ochoa, Juan Pablo
A1 Mirelis, Jesus G.
A1 Espinosa, Maria Angeles
A1 Navarro, Marina
A1 Gallego-Delgado, Maria
A1 Barriales-Villa, Roberto
A1 Robles-Mezcua, Ainhoa
A1 Basurte-Elorz, Maria Teresa
A1 Garcia-Moreno, Laura Gutierrez
A1 Climent, Vicente
A1 Jimenez-Jaimez, Juan
A1 Mogollon-Jimenez, Maria Victoria
A1 Lopez, Javier
A1 Pena-Pena, Maria Luisa
A1 Garcia-Alvarez, Ana
A1 Brion, Maria
A1 Ripoll-Vera, Tomas
A1 Palomino-Doza, Julian
A1 Tiron, Coloma
A1 Idiazabal, Uxua
A1 Brogger, Maria Noel
A1 Garcia-Hernandez, Soledad
A1 Restrepo-Cordoba, Maria Alejandra
A1 Gonzalez-Lopez, Esther
A1 Mendez, Irene
A1 Sabater, Maria
A1 Villacorta, Eduardo
A1 Larranaga-Moreira, Jose M.
A1 Abecia, Ana
A1 Fernandez, Ana Isabel
A1 Garcia-Pinilla, Jose M.
A1 Rodriguez-Palomares, Jose F.
A1 Gimeno-Blanes, Juan Ramon
A1 Bayes-Genis, Antoni
A1 Lara-Pezzi, Enrique
A1 Dominguez, Fernando
A1 Garcia-Pavia, Pablo
K1 dilated cardiomyopathy
K1 genetics
K1 heart failure
K1 left ventricular reverse remodeling
K1 mutation
K1 prognosis
K1 sudden cardiac death
K1 ventricular arrhythmia
K1 Risk
K1 Defibrillator
K1 Guidelines
K1 Management
K1 Statement
AB BACKGROUND The clinical relevance of genetic variants in nonischemic dilated cardiomyopathy (DCM) is unsettled. OBJECTIVES The study sought to assess the prognostic impact of disease-causing genetic variants in DCM. METHODS Baseline and longitudinal clinical data from 1,005 genotyped DCM probands were retrospectively collected at 20 centers. A total of 372 (37%) patients had pathogenic or likely pathogenic variants (genotype positive) and 633 (63%) were genotype negative. The primary endpoint was a composite of major adverse cardiovascular events. Secondary endpoints were end-stage heart failure (ESHF), malignant ventricular arrhythmia (MVA), and left ventricular reverse remodeling (LVRR) RESULTS After a median follow-up of 4.04 years (interquartile range: 1.70-7.50 years), the primary endpoint had occurred in 118 (31.7%) patients in the genotype-positive group and in 125 (19.8%) patients in the genotype-negative group (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.17-1.94; P = 0.001). ESHF occurred in 60 (16.1%) genotype-positive patients and in 55 (8.7%) genotype-negative patients (HR: 1.67; 95% CI: 1.16-2.41; P = 0.006). MVA occurred in 73 (19.6%) genotype-positive patients and in 77 (12.2%) genotype-negative patients (HR: 1.50; 95% CI: 1.092.07; P = 0.013). LVRR occurred in 39.6% in the genotype-positive group and in 46.2% in the genotype-negative group (P = 0.047). Among individuals with baseline left ventricular ejection fraction #35%, genotype-positive patients exhibited more major adverse cardiovascular events, ESHF, and MVA than their genotype-negative peers (all P
PB Elsevier science inc
SN 0735-1097
YR 2021
FD 2021-10-18
LK https://hdl.handle.net/10668/26487
UL https://hdl.handle.net/10668/26487
LA en
DS RISalud
RD Apr 18, 2025